Burzynski Research Institute, Inc. engages in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the trade name Antineoplastons. The company was founded by Stanislaw R. Burzynski in 1984 and is headquartered in Houston, TX.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company